Quarterly report · Q1
4587.TEDINET S100QQKF
Period2023-01-01 → 2023-03-31
Filed2023-05-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Amended by S100S6T6 (2023-11-09).
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.0bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥26.9bn | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥420m | 2022-01-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Operating income | −¥267m | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | −¥1.2bn | 2022-01-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥400m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.7bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥1.1bn | 2022-01-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥249m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥829m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥249m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥829m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥59.8bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥63.9bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥52.9bn | at 2022-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥28.0bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥31.8bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥31.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥32.0bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥24.7bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥25.4bn | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥31.8bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥32.0bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥24.7bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥11.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥5.2bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥10.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥7.7bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥83m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥8m | 2022-01-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥381m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥27.4bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥23.7bn | 2022-01-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥1.1bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥20.8bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥22.2bn | 2022-01-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-1.92 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥58.19 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-6.39 | 2022-01-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-1.92 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥58.14 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-6.39 | 2022-01-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 53.2% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 46.6% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 13
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥3m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥978m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥978m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥381m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥4.0bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥4.0bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥3m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥136m |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥5.0bn |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥5.0bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥3m |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | −¥244m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 486
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)上 野 直 樹 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)猪 俣 雅 弘 | |
| Number of submission | FilingDateInstant | 1 | |
| Revenue IFRS (5-year summary) | Prior1YTDDuration | 419526000 | JPY |
| Revenue IFRS (5-year summary) | CurrentYTDDuration | 4963470000 | JPY |
| Revenue IFRS (5-year summary) | Prior1YearDuration | 26852430000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1YTDDuration | -1123765000 | JPY |
| Profit loss before tax IFRS (5-year summary) | CurrentYTDDuration | -399914000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1YearDuration | 6653325000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior1YTDDuration | -829296000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | CurrentYTDDuration | -248801000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior1YearDuration | 7554358000 | JPY |
| Profit loss IFRS (5-year summary) | Prior1YTDDuration | -829296000 | JPY |
| Profit loss IFRS (5-year summary) | CurrentYTDDuration | -248801000 | JPY |
| Profit loss IFRS (5-year summary) | Prior1YearDuration | 7554358000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior1YTDDuration | -681906000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | CurrentYTDDuration | -234467000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior1YearDuration | 6606348000 | JPY |
| Comprehensive income IFRS (5-year summary) | Prior1YTDDuration | -681906000 | JPY |
| Comprehensive income IFRS (5-year summary) | CurrentYTDDuration | -234467000 | JPY |
| Comprehensive income IFRS (5-year summary) | Prior1YearDuration | 6606348000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | Prior1QuarterInstant | 24675042000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | CurrentQuarterInstant | 31812012000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | Prior1YearInstant | 32041465000 | JPY |
| Total assets IFRS (5-year summary) | Prior1QuarterInstant | 52898040000 | JPY |
| Total assets IFRS (5-year summary) | CurrentQuarterInstant | 59776628000 | JPY |
| Total assets IFRS (5-year summary) | Prior1YearInstant | 63865200000 | JPY |
| Basic earnings loss per share IFRS (5-year summary) | Prior1YTDDuration | -6.39 | |
| Basic earnings loss per share IFRS (5-year summary) | CurrentYTDDuration | -1.92 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior1YearDuration | 58.19 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior1YTDDuration | -6.39 | |
| Diluted earnings loss per share IFRS (5-year summary) | CurrentYTDDuration | -1.92 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior1YearDuration | 58.14 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior1QuarterInstant | 0.466 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | CurrentQuarterInstant | 0.532 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior1YearInstant | 0.502 | |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior1YTDDuration | -8387000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | CurrentYTDDuration | 7737043000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior1YearDuration | -82929000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior1YTDDuration | -23743690000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | CurrentYTDDuration | -380637000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior1YearDuration | -27377217000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1YTDDuration | 22187112000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | CurrentYTDDuration | -1140441000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1YearDuration | 20789451000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1QuarterInstant | 10277478000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | CurrentQuarterInstant | 11626423000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1YearInstant | 5247665000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |